Vaccines for preventing Japanese encephalitis - PubMed (original) (raw)

Review

Vaccines for preventing Japanese encephalitis

K L Schiøler et al. Cochrane Database Syst Rev. 2007.

Abstract

Background: Vaccination is recognized as the only practical measure for preventing Japanese encephalitis. Production shortage, costs, and issues of licensure impair vaccination programmes in many affected countries. Concerns over vaccine effectiveness and safety also have a negative impact on acceptance and uptake.

Objectives: To evaluate vaccines for preventing Japanese encephalitis in terms of effectiveness, adverse events, and immunogenicity.

Search strategy: In March 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE, EMBASE, LILACS, BIOSIS, and reference lists. We also attempted to contact corresponding authors and vaccine companies.

Selection criteria: Randomized controlled trials (RCTs), including cluster-RCTs, comparing Japanese encephalitis vaccines with placebo (inert agent or unrelated vaccine), no intervention, or alternative Japanese encephalitis vaccine.

Data collection and analysis: Authors independently extracted data and assessed methodological quality. Dichotomous data were compared with relative risks and a 95% confidence interval (CI), and converted into percentage vaccine efficacy.

Main results: Eight RCTs involving 358,750 participants were included. These trials investigated two available and three pre-licensure vaccines. Two RCTs assessing efficacy of the commercially available inactivated Nakayama vaccine were identified. A two-dose schedule of the licensed vaccine provided significant protection of 95% (95% CI 10% to 100%) for one year only, while two doses of an unpurified precursor vaccine protected children by 81% (95% CI 45% to 94%) in year one and by 59% (95% CI 2% to 83%) in year two. Serious adverse events were not observed. Mild and moderate episodes of injection site soreness, fever, headache, and nausea were reported in less than 6% of children receiving inactivated vaccine compared to 0.6% of unvaccinated controls. One cluster-RCT compared the live-attenuated SA14-14-2 vaccine (widely used in China) with no intervention measuring adverse events. Fever was reported in 2.7% of vaccinees compared to 3.1% of controls, while 0.1% of both groups suffered diarrhoea or seizures. Four small pre-licensure RCTs assessing a genetically engineered vaccine and two cell culture-derived inactivated vaccines revealed high immunogenicity and relative safety.

Authors' conclusions: Only one of the three currently used vaccines has been assessed for efficacy in a RCT. Other RCTs have assessed their safety, however, and they appear to cause only occasional mild or moderate adverse events. Further trials of effectiveness and safety are needed for the currently used vaccines, especially concerning dose levels and schedules. Trials investigating several new vaccines are planned or in progress.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

Analysis 1.1

Analysis 1.1

Comparison 1 Inactivated Nakayama vaccine (unpurified precursor) vs placebo, Outcome 1 Disease prevention: Japanese encephalitis cases by dose schedule and year after vaccination.

Analysis 2.1

Analysis 2.1

Comparison 2 Inactivated Nakayama and Nakayama + Beijing‐1 vaccines vs placebo, Outcome 1 Disease prevention: Japanese encephalitis cases by year after vaccination.

Analysis 3.1

Analysis 3.1

Comparison 3 Inactivated Nakayama vaccine vs Nakayama + Beijing‐1 vaccine, Outcome 1 Disease prevention: Japanese encephalitis cases by year after vaccination.

Update of

Similar articles

Cited by

References

References to studies included in this review

    1. Hoke CH. Lessons from field testing of non‐HIV vaccines: A field trial of Japanese encephalitis vaccine in Thailand. AIDS Research and Human Retroviruses 1993;9 Suppl 1:161‐7.
    2. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. New England Journal of Medicine 1988;319(10):608‐14. - PubMed
    1. Hsu TC, Chow LP, Wei HY, Chen CL, Hsu ST. A controlled field trial for an evaluation of effectiveness of mouse‐brain Japanese encephalitis vaccine. Taiwan Yi Xue Hui Za Zhi 1971;70(2):55‐62. - PubMed
    2. Hsu TC, Chow LP, Wei HY, Chen CL, Hsu ST, Huang CT, et al. A completed field trial for an evaluation of the effectiveness of mouse‐brain Japanese encephalitis vaccine. Conference on Japanese encephalitis virus vaccine. Tokyo: Igaku Shoin Ltd, 1971:258‐65.
    3. Hsu TC, Hsu ST. Supplementary report. Effectiveness of Japanese encephalitis vaccine: Study in the second year following vaccination. Conference on Japanese encephalitis virus vaccine. Tokyo: Igaku Shoin Ltd, 1971:266‐7.
    1. Kuzuhara S, Nakamura H, Hayashida K, Obata J, Abe M, Sonoda K, et al. Non‐clinical and phase I clinical trials of a Vero cell‐derived inactivated Japanese encephalitis vaccine. Vaccine 2003;21(31):4519‐26. - PubMed
    1. Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang S, C, et al. Short‐term safety of live attenuated Japanese encephalitis vaccine (SA14‐14‐2): results of a randomized trial with 26,239 subjects. Journal of Infectious Diseases 1997;176(5):1366‐9. - PubMed
    1. Lyons AG, Kuschner RA, Putnak JR, Eckels KH, Sun W, Towle AC, et al. Long term immunogenicity results of a phase 2 study of purified, inactivated vaccine against Japanese encephalitis virus (IC51, JE‐PIV). American Society of Tropical Medicine and Hygiene, 53rd Annual Meeting. 2004.

References to studies excluded from this review

    1. Ao J, Yu YX, Tang YS, Cui BC, Jia DJ, Li HM. Selection of a better immunogenic and highly attenuated live vaccine strain of Japanese encephalitis II. Safety and immunogenecity of live vaccine SA14‐14‐2 observed in inoculated children. Chinese Journal of Microbiology and Immunology 1983;3:245‐48.
    1. Rao Bhau LN, Singh G, Gowal D, Saxena SN, Kobayashi M, Oya A, et al. Safety & efficacy of Japanese encephalitis vaccine produced in India. Indian Journal of Medical Research 1988;88:301‐7. - PubMed
    2. Saxena SN, Bhau LN, Singh G, Gowal D, Sood YK, Misra CN, et al. Immune status of volunteers one year after administration of Japanese encephalitis vaccine produced in India. Indian Journal of Medical Research 1989;89:362‐7. - PubMed
    1. Chen HY, Ma FB, Zhang JL. Observation on safety of the live attenuated SA14‐14‐2 Japanese encephalitis vaccine. Chinese Journal of Epidemiology 1999;5(3).
    1. Defraites RF, Gambel JM, Hoke CH Jr, Sanchez JL, Withers BG, Karabatsos N, et al. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. American Journal of Tropical Medicine and Hygiene 1999;61(2):288‐93. - PubMed
    1. Gowal D, Tahlan AK. Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India. Indian Journal of Medical Research 1995;102:267‐71. - PubMed

References to studies awaiting assessment

    1. Acambis. Positive results from pivotal Phase 3 trials of Acambis’ JE vaccine. www.acambis.co.uk/default.asp?id=1724 30 October 2006 (accessed March 2007).
    1. Acambis. Acambis’ JE vaccine meets and exceeds primary endpoint in pivotal Phase 3 efficacy trial. www.acambis.com/default.asp?id=1839 1 March 2007 (accessed March 2007).
    1. Grachev VP, Sumarokov AA, Kharazian EG, Shkol'nik RIa, Karinskaia GA. Determination of the optimal dose of a cultured inactivated vaccine for preventing Japanese encephalitis. Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 1984;1:98‐103. - PubMed
    1. Ishikawa T. Development of new Japanese encephalitis vaccine. Nippon Rinsho 2005;63(12):2133‐7. - PubMed
    1. Sumarovkov AA, Grachev VP, Kharazian EG, Shkol'nik RIa, Vorob'eva MS. Comparative study of the reactogenicity and immunogenicity of new Soviet and commercial vaccines for preventing Japanese encephalitis. Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 1983;9:74‐9. - PubMed

Additional references

    1. Acambis. ChimeriVax™‐JE: A single‐dose JE vaccine for endemic markets and travellers. www.acambis.co.uk/default.asp?id=936(accessed March 2007).
    1. Andersen MM. Ronne T. Side‐effects with Japanese encephalitis vaccine. Lancet 1991;337(8748):1044. - PubMed
    1. Anonymous. Japanese Encephalitis virus infection in mosquitoes and its epidemiological implications. Indian Council of Medical Research (ICMR) Bulletin April, 2000;30(4):1‐7.
    1. Barrett AD. Japanese encephalitis and dengue vaccines. Biologicals 1997;25(1):27‐34. - PubMed
    1. Barrett AD. Current status of flavivirus vaccines. Annals of the New York Academy of Sciences 2001;951:262‐71. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources